Liraglutide Versus Insulin Mono-therapy in the Closed Loop Setting

Inclusion Criteria: * Age greater than 18 years and less than 40 years * Have had diabetes for at least 1 year, and in good control (HbA1C \< 8.5 %) * Be on continuous subcutaneous insulin infusion using an insulin pump * Menstruating women must have negative pregnancy test. * Hemoglobin (Hb) \> 12 g/dL * Either is not treated with or has been on a stable treatment regimen with any of the following medications for a minimum of 3 months prior to Screening: a. Oral contraceptives (female subjects)b. Antihypertensive agents c. Lipid-lowering agents d. Thyroid replacement therapy e. Antidepressant agents * For female subjects:a. Not breastfeeding b. Negative pregnancy test result (human chorionic gonadotropin, beta subunit \[βhCG\])at Screening c. If of childbearing potential, must practice and be willing to continue to practice appropriate birth control (defined as at least one method which results in a low failure rate, i.e., less than 1% per year, when used consistently and correctly, such as implants, injectable's, hormonal contraceptives, some intrauterine contraceptive devices, sexual abstinence, tubal ligation or occlusion, or a vasectomized partner)during the entire duration of the study and must not be planning to conceive * Should not have any alcohol or drug dependency as assessed by CRAFFT questionnaire. Exclusion Criteria: * Any chronic disease (leukemia, asthma, inflammatory bowel disease, cystic fibrosis, juvenile rheumatoid arthritis, etc., that directly, or as a result of treatment, directly or indirectly affect glucose homeostasis * Hemoglobin less than 12 g/dl * Positive pregnancy test in menstruating young women * Evidence or history of chemical abuse * HbA1c \> 8.5 % * Weight less than 50 Kg * History of gastro paresis and on medications that alter gastric emptying * History of Pancreatitis and impaired renal function * Hypoglycemic unawareness * History of sensitivity to 5-HT3 receptor antagonists * History of QT prolongation or any known cardio-vascular disease * Concomitant use of both Acetaminophen and vitamin C * Patients on glucocorticoid therapy * Known allergy to Liraglutide * Personal or family history of elevated calcitonin, calcitonin \>100 ng/L, medullary thyroid carcinoma or in patients with Multiple Endocrine Neoplasia (MEN) syndrome type 2.